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ABSTRACT
Background: Hydroxychloroquine may result
in cutaneous dyschromia. Older individuals
who are the victims of elder abuse can present
with bruising and resolving ecchymoses.
Purpose: The features of hydroxychloroquine-
associated hyperpigmentation are described,
the mucosal and skin manifestations of elder
abuse are reviewed, and the mucocutaneous
mimickers of elder abuse are summarized.
Case Report: An elderly woman being treated
with hydroxychloroquine for systemic lupus
erythematosus developed drug-associated black
and blue pigmentation of her skin. The
dyschromia was misinterpreted by her
clinician as elder abuse and Adult Protective
Services was notified. The family was eventually
cleared of suspected elder abuse. A skin biopsy
of the patient’s dyschromia confirmed the
diagnosis of hydroxychloroquine-associated
hyperpigmentation.
Conclusion: Hyperpigmentation of skin,
mucosa, and nails can be observed in patients
treated with antimalarials, including
hydroxychloroquine. Elder abuse is a significant
and underreported problem in seniors.
Cutaneous findings can aid in the discovery of
physical abuse, sexual abuse, and self-neglect in
elderly individuals. However, medication-
associated effects, systemic conditions, and
accidental external injuries can mimic elder
abuse. Therefore, a complete medical history
and appropriate laboratory evaluation, including
skin biopsy, should be conducted when the
diagnosis of elder abuse is suspected.
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of nails, mucosa, and skin [1–5]. Retrospective
studies cite the incidence of drug-related
hyperpigmentation from hydroxychloroquine
to be as high as 33% of individuals [6].
Elder abuse is a cause of significant morbidity
and mortality in older individuals [7–9]. Elder
abuse and neglect is a significant problem in
seniors and the annual reported incidence
ranges from 2% to 10% [9, 10]; yet, it is
suspected that only 1 in 5 cases is actually
reported [9]. Indeed, older individuals who are
the victims of elder abuse can present with
bruising and resolving ecchymoses.
In the present paper, an older woman with
hydroxychloroquine-associated cutaneous
pigmentation that was misinterpreted as elder
abuse is described, mucosal and skin
manifestations of elder abuse are reviewed,
and cutaneous mimickers of elder abuse are
summarized.
CASE REPORT
A 66-year-old white woman presented for an
evaluation of her skin. Informed consent was
obtained from the patient for being included in
the study. Additional informed consent was
obtained from all patients for which identifying
information is included in this article. The
patient’s past medical history was significant
for systemic lupus erythematosus and
myasthenia gravis. Since 1980, the patient has
been treated with hydroxychloroquine at a
daily dose of 400 mg.
There was diffuse hyperpigmentation. The
patient’s forehead, face, neck, v-area of the
upper central chest, and upper back were black
(Figs. 1, 2), and her right upper chest was blue
(Figs. 1, 3). Hyperpigmentation was absent from
her oral mucosa and nails.
Five years earlier, the patient had visited a
new clinician on a Friday afternoon. The
patient’s clinician misinterpreted her black
and blue dyschromia to be trauma-induced
and had notified Adult Protective Services. The
following Monday morning, a worker from the
agency was at her home to investigate the
family for elder abuse. Eventually the situation
was resolved and the family was cleared of all
suspicion of elder abuse.
During her current cutaneous evaluation, a
skin biopsy from the area of blue dyschromia on
the patient’s right upper chest was performed.
Microscopic examination showed both
intracellular and extracellular yellow-to-brown
granules scattered throughout the reticular
dermis. Pigmented granules were seen between
the collagen bundles with some accentuation
Fig. 1 Diffuse black hyperpigmentation of the forehead,
face, neck, and v-area of the upper central chest of a
woman with systemic lupus erythematosus who has been
receiving hydroxychloroquine for more than 30 years.
There is also blue dyschromia of the upper right chest.
The infusion port on her left chest is for plasmapheresis
treatment of her myasthenia gravis
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around eccrine glands. The granules stained
positively for both Fontana Masson and Perl’s
stains.
Correlation of the patient’s medical history,
clinical presentation, and pathology findings
confirmed the diagnosis of hydroxychloroquine-
induced hyperpigmentation.
DISCUSSION
Hydroxychloroquine, which has a
4-aminoquinoline nucleus, is used in the
management of malaria, rheumatologic
disorders, and dermatologic conditions, such
as lupus erythematosus, polymorphous light
eruption, and porphyria cutanea tarda [1, 5].
Most commonly, its use can result in
hyperpigmentation of the forehead, hard
palate, forearms, and shins [2, 3]; it can also
cause pigmentation that appears on the cheek
mucosa and nails [6, 11]. The development of
hydroxychloroquine-associated cutaneous
dyschromia is not so rare and can present as
black, blue-gray or blue discoloration in
photodistributed areas or skin sites protected
from the sun [6].
Microscopic examination of
hydroxychloroquine hyperpigmentation shows
yellow-brown, non-refractile, coarsely granular
pigmented deposits, amongst the collagen fibers
in the superficial dermis; they are also located
not only within macrophages but also
extracellularly [12–14]. The granules stain
positive for either melanin [15] or both
melanin and hemosiderin [13, 16]. It has been
postulated that this accumulation of melanin,
hemosiderin, or both results in the
pigmentation observed clinically [6, 12]. In
addition, it has also been hypothesized that
there is a relationship between the development
of pigment changes and the length of use of
hydroxychloroquine [6].
Hydroxychloroquine pigmentation can occur
within 1 year after starting therapy [4, 12,
13, 17]. The skin discoloration has no systemic
adverse sequelae. After discontinuation of the
Fig. 2 Diffuse hydroxychloroquine-associated black
hyperpigmentation involving the entire upper back,
originally misinterpreted as elder abuse, in a 66-year-old
woman with systemic lupus erythematosus
Fig. 3 A closer view of her upper right chest shows
biopsy-conﬁrmed hydroxychloroquine-associated blue
pigmentation of the skin
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drug, the hydroxychloroquine-associated
pigmentation slowly fades. The reported time
for spontaneous regression of the
hyperpigmentation ranges from 2 to 6 months
[6, 12]; however, persistent cutaneous
hyperpigmentation even 1 year after
discontinuation of therapy has been observed
[18].
The present patient had black
hydroxychloroquine-associated hyperpigmentation
on her face, v-area of her upper central chest,
and other sites that were exposed to the sun. In
addition, the patient had drug-related blue
patches of dyschromia on sun protected areas,
such as the right side of her chest, above her
breast. Microscopic examination was significant
for not only intracellular hydroxychloroquine
granules but also extracellular granules; this
finding correlates with the patient’s clinical
history of still receiving hydroxychloroquine;
hence, new particles continue to be deposited in
the dermis and have not all been engulfed by
macrophages.
Elder abuse—also referred to as abuse of older
adults and mistreatment of seniors—is: (1) any
intentional action (by either a person who has a
trusted relationship with the older individual or
a caregiver) that results in either serious risk of
harm or actual injury to a vulnerable elder, or
(2) failure of a caregiver to either protect the
older adult from harm or satisfy the senior’s
basic needs. Several types of elder abuse exist:
abandonment, emotional or psychological
abuse, financial or material exploitation,
neglect, physical abuse, resident-to-resident
aggression, self-neglect, and sexual abuse.
Most commonly, the perpetrator of elder
abuse is a family member [6–8].
Cutaneous manifestations of elder abuse
include signs of physical abuse, self-neglect,
and sexual abuse (Table 1) [10, 19]. However,
mucosal and skin lesions of systemic conditions
or accidental external injury can mimic elder
abuse (Table 2) [10, 19]. Chang et al. [19] and
Palmer et al. [10] presented brief reports with
accompanying illustrations of elder abuse
mimickers: (1) the chronically sun-damaged
extensor surface of an elderly woman’s
forearm with suspected traumatic purpura,
which actually represented Bateman’s purpura
(also referred to as senile purpura or solar
purpura) following minor incidental bumping
of the skin during routine activity; (2) digitate
purpura on the abdomen of an older man
suspicious for a trauma-inflicted etiology that
actually appeared following deep palpation by
the physician in the setting of the patient’s
hepatic coagulopathy; and (3) purpura in the
inguinal folds of an older man mistaken by
emergency providers to represent blunt trauma
with intraabdominal hemorrhage but actually
showed leukocytoclastic vasculitis on skin
biopsy.
The diffuse hyperpigmentation secondary to
hydroxychloroquine treatment of the patient in
the present report was misinterpreted as elder
abuse and the family was visited by Adult
Protective Services. Recently, True et al. [20]
described a patient who had rheumatoid
arthritis for which hydroxychloroquine was
given for many years with good clinical
results; subsequently, large areas of
hyperpigmentation developed over all
extremities, the torso, and the hairline. The
patient’s hyperpigmentation was so
pronounced that on one occasion, similar to
the present patient, health care personnel filed a
report of elder abuse [20].
A thorough history is paramount in
excluding other conditions that can mimic
elder abuse. In addition, laboratory studies
may be helpful to establish the diagnosis of a
medical infirmity masquerading as elder abuse.
Finally, similar to the present patient, a skin
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Irritant dermatitis from prolonged exposure to urine or
feces
Ulcers
Basal cell carcinoma (advanced)
Pressure-induced (over bony prominences)
Squamous cell carcinoma (advanced)
Vitamin deﬁciency
Acral dermatitis (zinc deﬁciency)
Cheilitis (vitamin B12, folic acid, or iron deﬁciency)
Glossitis (vitamin B12, folic acid, or iron deﬁciency)
Perioriﬁcial lesions (biotin or zinc deﬁciency)
Photosensitivity (vitamin B3 or vitamin B6-pellagra
deﬁciency)
Phrynoderma (keratosis pilaris-like lesions from vitamin A
deﬁciency)
Purpura or petechiae (vitamin C if perifollicular or
vitamin K deﬁciency)
Sexual abuse
Sexually transmitted skin disease lesionsa
Blisters (herpes simplex virus infection)
Candidiasis (possible human immunodeﬁciency virus-
associated)
Condyloma acuminata (human papillomavirus
infection)
Condyloma lata (secondary syphilis infection)





a The observation of these lesions is suspicious for elder abuse
especially when they occur in patients who do not have
decision-making capacity and who are, therefore, not able to
consent to sexual activity




Patients with age-related patterned (frontotemporal and vertex) hair loss
Blisters and bullae
Patients with primary autoimmune bullous diseases
Bruises on bony prominences, buttocks, dorsal feet, genitals, and inner thighs
Patients with limited mobility
Bruises usually on extensor extremities
Accidental injury in patients with medication-associated coagulopathy
Hyperpigmentation mimicking bruises
Patients receiving certain systemic medications:
Amiodarone, antimalarials, minocycline, or phenothiazines
Purpura: non-speciﬁc pattern
Corticosteroid-associated:
Sun exposed areas after mild trauma in patients on systemic corticosteroids
Sites of topical corticosteroid application
Vasculitis and vasculopathy
Purpura in shape of ﬁnger indentations around extremities
Caregiver’s efforts to aid patients who are immobile
Normal capillary fragility
Patients with conditions associated with coagulopathy
Purpura on extensor surfaces of sun exposed forearms
Bateman’s purpura (also referred to as senile purpura or solar purpura)a
Rash in stocking and glove distribution mimicking immersion burn
Contact dermatitis from socks, footwear, or mittens and glovesb
Sexual abuse
Anal ﬁssures and excoriation (mimicking trauma)
Constipation induced
Inﬂammatory bowel disease
Bleeding and bruising of the genitalia
Catheterization difﬁculty
Genital erosions and ulcers
Behcet disease
Lichen planus (erosive mucosal)
Squamous cell carcinoma
Genital excoriations and bleeding
Decreased estrogen levels in postmenopausal women
Penile annular conﬂuent erythema and subsequent hyperpigmentation
mimicking trauma
Fixed drug eruption (to drugs such as barbiturates, tetracycline, or stool
softeners)
Perineal maceration and irritation
Incontinence of stool and urine
Perineum with lesions morphologically similar to healed trauma-induced scars
Lichen sclerosus et atrophicus
a Dermal capillaries are unsupported and susceptible to injury because of
degeneration of extracellular matrix components
b The condition is usually pruritic instead of painful
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biopsy may be essential to exclude elder abuse
and establish the correct diagnosis.
CONCLUSION
Antimalarials, such as hydroxychloroquine, are
still a mainstay therapy in the management of
patients with lupus erythematosus and
rheumatoid arthritis. Physical abuse of elders
can be suspected based upon associated
cutaneous findings, such as patterned shape or
distribution of lesions, various stages of healing
lesions, signs of blunt trauma, bilateral or
parallel injuries on extremities, and alopecia
with irregular patches of hair loss and hairs of
varying lengths or many short hairs. However,
hyperpigmentation from either accidental
external trauma, cutaneous conditions,
mucocutaneous manifestations of medications,
or systemic disorders can mimic the
morphologic features of elder abuse (Table 3)
[1–4, 21–39]. Hydroxychloroquine-associated
hyperpigmentation in an elderly woman was
clinically misinterpreted as elder abuse resulting
in notification of Adult Protective Services by
the clinician; skin biopsy subsequently
confirmed the etiology of her diffuse black and
blue dyschromia. When the diagnosis of elder
abuse is entertained, a complete medical
history—including medications being taken by
the patient—should be conducted. Appropriate
laboratory studies, including skin biopsy, may
be helpful in establishing or excluding the
diagnosis of elder abuse.
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Benign pigmented purpuric eruption



















Blue toe syndrome [34]
DRESS syndrome (post baclofen, piracetam, and
mitoxantrone) [35]
Hemochromatosis [36]
Melanosis cutis (diffuse) [37]
Ochronosis (endogenous) [38]
POEMS syndrome (associated with Castleman’s
disease) [39]
DRESS drug rash with eosinophilia and systemic signs,
POEMS polyneuropathy, organomegaly, endocrinopathy,
monoclonal protein, and skin changes
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